Weekly Competitive Intelligence Briefing — Keytruda

Week ending August 19, 2026

1. Competitive landscape snapshot

This is a baseline week: no prior-week comparison is available.

The tagged competitor_mentions field records zero answer-level mentions for all competitors. Accordingly, no competitor has measurable mention share in answers about Keytruda, and there are no captured incidental mentions.

There is nevertheless clear prompt-level comparative interest:

• Opdivo (nivolumab): named in 3 of 5 brand questions, representing 18 responses.
• Tecentriq (atezolizumab): named in 1 question, representing 6 responses.
• Total explicit comparison exposure: 24 of 30 brand responses.
• Incidental competitor mentions captured in answers: 0.

This distinction matters: Opdivo and Tecentriq are prominent in the questions being asked, but the current tagging does not show them being independently introduced by the models in their answers.

2. How the comparison is currently framed

The framing is predominantly balanced and conditional, rather than consistently favoring Keytruda or a competitor.

Against Opdivo, answers repeatedly describe both products as PD-1 inhibitors and say selection depends on cancer type, stage, biomarkers, approved indications, evidence, combinations, dosing, and access. One representative answer states that oncologists choose based on “cancer type/stage, biomarkers, trial evidence, approved indications” and practical factors. Another says claims that Keytruda is “more effective” are often based on “cross-trial comparison + interpretation,” not a universal head-to-head superiority finding.

The “more effective” question generated the strongest competitive-claim language: all six responses carried overclaim_language tags, including “superior,” “stronger,” “leading,” or “strongest.” However, because every response’s competitors_mentioned array is empty, the data does not establish a tagged answer-level co-occurrence or confirm that these terms were used to favor Keytruda over Opdivo. The excerpts instead generally hedge and emphasize similar or setting-dependent outcomes.

Against Tecentriq, the framing is also neutral: Keytruda is described as PD-1-directed and Tecentriq as PD-L1-directed, with treatment choice linked to indication, biomarker status, cancer setting, and combination strategy.

3. Movers — who’s gaining or losing ground

No movers can be identified. This is the first available week, previous_week_available is false, and trend_deltas_vs_previous_week is empty. Opdivo and Tecentriq should be treated as baseline comparison participants, not confirmed gainers or new entrants based on answer-level mention share.

4. Questions worth watching

1. “My oncologist mentioned Keytruda versus Opdivo… what are the key differences in how they’re positioned or prescribed?” — six responses; establishes the core head-to-head decision frame.
2. “When people say Keytruda is ‘more effective’… is that based on head-to-head trials, or mostly marketing talk compared with Opdivo?” — six responses; highest concentration of superiority-language tags.
3. “What’s the difference between Keytruda and Tecentriq… in terms of treatment choice?” — six responses; tests whether PD-1 versus PD-L1 becomes a meaningful positioning distinction.
4. “Is Keytruda… interchangeable with something else?” — six responses; biosimilar/substitution framing could become strategically important, although no named competitor was captured.

5. Recommended actions

1. Establish next week’s competitor baseline and monitor whether Opdivo or Tecentriq begin appearing in answer-level competitor_mentions.
2. Track the Opdivo comparison cluster, particularly the “more effective” question and its superiority-language frequency.
3. Flag the current framing for competitive awareness: AI answers are positioning Keytruda–Opdivo choice as indication- and biomarker-dependent, not a universal winner-take-all comparison.
4. Review mention-tagging completeness before interpreting future shifts; the gap between 24 explicit comparative responses and zero answer-level mentions limits competitive share analysis.
5. Continue routine monitoring of Tecentriq and biosimilar/substitution questions for evidence of a sustained positioning shift.